BRIEF-EMA Recommends Measures To Minimise Serious Side Effects Risks With JAK Inhibitors For Chronic Inflammatory Disorders
- Country:
- United Kingdom
EMA: * EMA: EMA RECOMMENDS MEASURES TO MINIMISE RISK OF SERIOUS SIDE EFFECTS WITH JANUS KINASE INHIBITORS FOR CHRONIC INFLAMMATORY DISORDERS
* EMA: SIDE EFFECTS INCLUDE CARDIOVASCULAR CONDITIONS, BLOOD CLOTS, CANCER AND SERIOUS INFECTIONS * EMA: REVIEW CONFIRM XELJANZ UPS MAJOR CARDIOVASCULAR PROBLEMS, CANCER, VTE, INFECTIONS, DEATH RISK DUE TO CAUSE WHEN COMPARED TO TNF-ALPHA INHIBITORS
ALSO READ
-
Fostering Unity: Enhancing Cancer Care Through Collaborative Efforts
-
Cancer Care Revolutionized: Fortis Cancer Institute Shines in 'Molecules of Hope'
-
Netanyahu's Battle with Prostate Cancer: A Leader's Private Struggle Publicly Revealed
-
Netanyahu Overcomes Prostate Cancer Amid Political Tensions
-
Heart's Mechanical Strain: A Natural Cancer Suppressant?
Google News